Skip to main content
ConductScienceScienceDex

Fernando Aleman Guillen

NIH Rank #7116
Unclaimed recordClaim profile
  • Early Career

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 11700509Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2024 onlyCareer claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.

NIH Funding · FY2024

Linked Award Amount
$1.7M
Full award amounts, FY2024
Award Records
3
Records listing this PI
Award-Linked Rank
#7,116
By linked amount among FY2024 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Fernando Aleman Guillen. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2024 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award data coverage

ScienceDex currently has one fiscal year of PI ranking data for this record. This does not establish the first NIH award or current employer.

Single fiscal year on record (FY2024): $1.7M in linked award amounts across 3 award records · Award-linked rank #7116.

FY2024 award records by amount

NIH award records listing Fernando Aleman Guillen as a PI. Multi-PI records show the full award amount for context.

  • 5U44NS122114-04U44
    Preclinical optimization of a gene therapy for erythromelalgia and chronic pain
    Navega Therapeutics, Inc.
    $1.5M
    award amount
  • 3U44NS122114-04S1U44
    Preclinical optimization of a gene therapy for erythromelalgia and chronic pain
    Navega Therapeutics, Inc.
    $98.7K
    award amount
  • 3U44NS122114-03S1U44
    Preclinical optimization of a gene therapy for erythromelalgia and chronic pain
    Navega Therapeutics, Inc.
    $74.7K
    award amount

Award organization

Organizations that administered FY2024 awards listing Fernando Aleman Guillen as a PI.

FY2024 award administered by Navega Therapeutics, Inc. (CA).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    Navega Therapeutics, Inc.
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    Entered Top 50% Nationally
    Ranked #7116

Shared-award investigators

Other investigators listed on at least one of the same NIH award records as Fernando Aleman Guillen.

Ana Maria Moreno
Navega Therapeutics, Inc.
3
shared awards

Explore further

Find collaborators for Fernando Aleman Guillen

Search NIH-funded principal investigators by topic, department, or activity.

Open Find Collaborators →

Benchmark grant budgets

Compare median NIH grant budgets across departments, mechanisms, and years.

Open Grant Budget Benchmark →